Heart Test Laboratories, Inc. (HSCS)
| Market Cap | 14.72M |
| Revenue (ttm) | 25,174 |
| Net Income (ttm) | -3.63M |
| Shares Out | 8.04M |
| EPS (ttm) | -0.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,110 |
| Open | 1.94 |
| Previous Close | 1.98 |
| Day's Range | 1.81 - 2.08 |
| 52-Week Range | 1.70 - 3.21 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About HSCS
Heart Test Laboratories is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Our objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which ha... [Read more...]
Financial Performance
In 2021, HSCS's revenue was $25,604, a decrease of -60.11% compared to the previous year's $64,182. Losses were -$2.45 million, -35.66% less than in 2020.
Financial StatementsNews
Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing
SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI...